Evidence map›Paper›PMID 34057572›Full record

ArticleCancer chemotherapy and pharmacology2021

Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic-pharmacodynamic real-life study.

Lauriane Goldwirt, B Louveau, B Baroudjian, C Allayous, F Jouenne, L Da Meda, L-T Vu, H Sauvageon, F Herms, J Delyon and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lauriane Goldwirt *Department of Pharmacology and Tumor Genomics , AP-HP, Hôpital Saint-Louis, Inserm, UMRS976 Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, 1 avenue Claude Vellefaux, 75010, Paris, France. lauriane.goldwirt@aphp.fr.ORCID http://orcid.org/0000-0001-9741-803X
B Louveau *Department of Pharmacology and Tumor Genomics , AP-HP, Hôpital Saint-Louis, Inserm, UMRS976 Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, 1 avenue Claude Vellefaux, 75010, Paris, France.
B BaroudjianDepartment of Dermatology, AP-HP, Hôpital Saint-Louis, Inserm, UMRS976, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
C AllayousDepartment of Dermatology, AP-HP, Hôpital Saint-Louis, Inserm, UMRS976, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
F JouenneDepartment of Pharmacology and Tumor Genomics , AP-HP, Hôpital Saint-Louis, Inserm, UMRS976 Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, 1 avenue Claude Vellefaux, 75010, Paris, France.
L Da MedaDepartment of Dermatology, AP-HP, Hôpital Saint-Louis, Inserm, UMRS976, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
L-T VuDepartment of Dermatology, AP-HP, Hôpital Saint-Louis, Inserm, UMRS976, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
H SauvageonDepartment of Pharmacology and Tumor Genomics , AP-HP, Hôpital Saint-Louis, Inserm, UMRS976 Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, 1 avenue Claude Vellefaux, 75010, Paris, France.
F HermsDepartment of Dermatology, AP-HP, Hôpital Saint-Louis, Inserm, UMRS976, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
J DelyonDepartment of Dermatology, AP-HP, Hôpital Saint-Louis, Inserm, UMRS976, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
C Lebbé *Department of Dermatology, AP-HP, Hôpital Saint-Louis, Inserm, UMRS976, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
S Mourah *Department of Pharmacology and Tumor Genomics , AP-HP, Hôpital Saint-Louis, Inserm, UMRS976 Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, 1 avenue Claude Vellefaux, 75010, Paris, France.
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDabrafenib plus trametinib combination has greatly improved survival in BRAFV600

methodsBRAFV600

resultsFifty patients (comprising 4 AJCC stage IIIc and 46 stage IV) were included. Median PFS reached 11.4 months, and overall response rate 70%. Fifty percent of patients experienced ARAE (G3 n = 10, G4 n = 0). In univariate analysis, median dabrafenib C

conclusionIn this study, exposure-efficacy and tolerance analysis highlighted the interest of therapeutic drug monitoring to optimize therapeutic management in BRAFV600

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveBayes TheoremDrug MonitoringFemaleHumansImidazolesMaleMelanomaMiddle AgedMutationNeoplasm StagingOximesProgression-Free SurvivalProspective StudiesBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibDabrafenibMetastatic melanomaPharmacokinetic/pharmacodynamicTherapeutic drug monitoringTrametinib

Identifiers

PMID34057572
OpenAlexW3164187146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.